Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | UGCG | Q16739 | 2/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25240977 | 1.00 | EPHX2 (0.52) | EPHX2L3MBTL1TDP1FAAHGBA1 | |
| SCHEMBL25215220 | 1.00 | EPHX2 (0.52) | EPHX2L3MBTL1TDP1FAAHGBA1 | |
| SCHEMBL25269510 | 0.94 | EPHX2 (0.57) | EPHX2L3MBTL1TDP1FAAHTSHR | |
| SCHEMBL10081325 | 0.94 | EPHX2 (0.57) | EPHX2L3MBTL1TDP1FAAHTSHR | |
| SCHEMBL19032713 | 0.94 | EPHX2 (0.57) | EPHX2L3MBTL1TDP1FAAHTSHR | |
| SCHEMBL25212789 | 0.89 | MAPT (0.54) | EPHX2L3MBTL1TDP1FAAHHTT | |
| SCHEMBL8984536 | 0.89 | MAPT (0.54) | EPHX2L3MBTL1TDP1FAAHHTT | |
| SCHEMBL25213662 | 0.89 | MAPT (0.54) | EPHX2L3MBTL1TDP1FAAHHTT | |
| SCHEMBL25210921 | 0.89 | MAPT (0.54) | EPHX2L3MBTL1TDP1FAAHHTT | |
| SCHEMBL25208054 | 0.88 | L3MBTL1 (0.54) | EPHX2L3MBTL1TDP1GBA1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4433464-A1 | NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | Astrazeneca AB (SE) | 2024-09-25 | — | — | EP | disclosed |
| CN-118234713-A | Novel lipids for delivery of nucleic acid segments | 阿斯利康(瑞典)有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20230181482-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-06-15 | — | — | US | disclosed |
| US-20230181482-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-06-15 | — | — | US | disclosed |
| US-20230181482-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-06-15 | — | — | US | disclosed |
| WO-2023089522-A1 | NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023089522-A1 | NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181482-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | SNRPA, F12, ABCB4 | EPHX2 2992/4885L3MBTL1 480/4885TDP1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.